world
Fármaco combinado experimental de Lilly supera a Zepbound en ensayo clínico para perder peso
El Economista
September 30, 2026
via El EconomistaYou're reading one story from Newsaly
Newsaly brings together 60,000+ newspaper articles, 30,000+ podcasts and 10,000+ magazine articles from around the world.
A World Of News, One Window.
Explore Today's News
Eli Lilly anunció que su fármaco experimental combinado para la pérdida de peso superó a su superventas Zepbound en un ensayo comparativo directo, lo que intensifica la competencia con Novo Nordisk por nuevas terapias contra la obesidad más eficaces.
Read the full story
Explore More On Newsaly
Voices (0)
Share a 15-second voice reaction. Voices automatically disappear after 10 days.
Sign in to record a voice on this article.
Be the first to share a voice on this article.